Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
Transactions in Connection with Share Buy-back Program
09:33am, Monday, 23'rd Feb 2026
Company Announcement COPENHAGEN, Denmark; February 23, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
10:05am, Friday, 20'th Feb 2026
Company Announcement COPENHAGEN, Denmark; February 20, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/52
Genmab A/S Q4 Earnings Call Highlights
02:04am, Thursday, 19'th Feb 2026
Genmab A/S (NASDAQ: GMAB) executives told investors the company delivered on its 2025 priorities of accelerating late-stage pipeline development, maximizing commercial medicines, and executing its cap
Notice to Convene the Annual General Meeting of Genmab A/S
09:09am, Wednesday, 18'th Feb 2026
Company Announcement Genmab A/S to hold Annual General Meeting on Thursday March 19, 2026 COPENHAGEN, Denmark; February 18, 2026 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Thu
Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript
04:14pm, Tuesday, 17'th Feb 2026
Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript
Genmab Announces Initiation of Share Buy-Back Program
03:14pm, Tuesday, 17'th Feb 2026
Company Announcement Repurchase of up to 342,130 shares with a maximum aggregate total value of 725 million DKK Honoring our commitments under the Restricted Stock Unit program Completion expected no
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
11:23am, Tuesday, 17'th Feb 2026
Media Release COPENHAGEN, Denmark; February 17, 2026 Genmab filed Form 20-F for the financial year 2025 with the U.S. SEC Genmab A/S (Nasdaq: GMAB ) a nnounced today that it has filed its Annual Repor
Genmab Publishes 2025 Annual Report
11:01am, Tuesday, 17'th Feb 2026
Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Sees Significant Decrease in Short Interest
04:12am, Monday, 16'th Feb 2026
Genmab A/S Sponsored ADR (NASDAQ: GMAB - Get Free Report) was the recipient of a large decline in short interest during the month of January. As of January 30th, there was short interest totaling 8,41
279,932 Shares in Genmab A/S Sponsored ADR $GMAB Bought by Cibc World Market Inc.
03:56am, Saturday, 14'th Feb 2026
Cibc World Market Inc. purchased a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ: GMAB) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchang
Is the Options Market Predicting a Spike in Genmab Stock?
10:01am, Friday, 13'th Feb 2026
Investors need to pay close attention to GMAB stock based on the movements in the options market lately.
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
10:36am, Friday, 30'th Jan 2026
/PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
10:30pm, Thursday, 29'th Jan 2026
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability
Grant of Restricted Stock Units and Warrants to Employees in Genmab
12:49pm, Thursday, 29'th Jan 2026
Company Announcement COPENHAGEN, Denmark; January 29, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Analysts
03:06am, Saturday, 24'th Jan 2026
Shares of Genmab A/S Sponsored ADR (NASDAQ: GMAB - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the ten brokerages that are presently covering the firm, Marketbeat
